Drug-induced hypophosphatemia: current insights
E Megapanou, M Florentin, H Milionis, M Elisaf… - Drug safety, 2020 - Springer
Phosphate is actively involved in many important biochemical pathways, such as energy
and nucleic acid metabolism, cellular signaling, and bone formation. Hypophosphatemia …
and nucleic acid metabolism, cellular signaling, and bone formation. Hypophosphatemia …
Medication-induced hypophosphatemia: a review
G Liamis, HJ Milionis, M Elisaf - QJM: An International Journal of …, 2010 - academic.oup.com
Abstract Hypophosphatemia (serum phosphorus concentration< 2.5 mg/dl, 0.8 mmol/l),
although rare in the general population, is commonly observed in hospitalized patients and …
although rare in the general population, is commonly observed in hospitalized patients and …
Hypophosphatemia in cancer patients
S Adhikari, O Mamlouk, H Rondon-Berrios… - Clinical Kidney …, 2021 - academic.oup.com
Dysregulation of phosphorus homeostasis resulting in hypophosphatemia is common in
cancer patients and can result in serious complications and impact outcomes. Several …
cancer patients and can result in serious complications and impact outcomes. Several …
Hypophosphatemia: an update on its etiology and treatment
A Gaasbeek, AE Meinders - The American journal of medicine, 2005 - Elsevier
Phosphate plays a key role in several biological processes. In recent years, new insights
have been obtained into the regulation of the phosphate metabolism, including a growing …
have been obtained into the regulation of the phosphate metabolism, including a growing …
[HTML][HTML] Hyperphosphatemia management in patients with chronic kidney disease
AM Shaman, SR Kowalski - Saudi Pharmaceutical Journal, 2016 - Elsevier
Hyperphosphatemia in chronic kidney disease (CKD) patients is a potentially life altering
condition that can lead to cardiovascular calcification, metabolic bone disease (renal …
condition that can lead to cardiovascular calcification, metabolic bone disease (renal …
Proton pump inhibitor–associated hypomagnesemia: what do FDA data tell us?
CP Luk, R Parsons, YP Lee… - Annals of …, 2013 - journals.sagepub.com
BACKGROUND: Proton pump inhibitors (PPIs) are a class of medications indicated for the
treatment of gastric acid–related diseases. Hypomagnesemia is a rare but serious adverse …
treatment of gastric acid–related diseases. Hypomagnesemia is a rare but serious adverse …
Hypophosphatemia: a practical guide to evaluation and management
PJ Tebben - Endocrine Practice, 2022 - Elsevier
Phosphate plays a critical and diverse role in human physiology. In addition to its
importance in skeletal mineralization, it is essential for energy homeostasis, enzyme …
importance in skeletal mineralization, it is essential for energy homeostasis, enzyme …
Approach to patients with hypophosphataemia
P Florenzano, C Cipriani, KL Roszko… - The Lancet Diabetes & …, 2020 - thelancet.com
Phosphate metabolism is an evolving area of basic and clinical research. In the past 15
years, knowledge on disturbances of phosphate homoeostasis has expanded, as has the …
years, knowledge on disturbances of phosphate homoeostasis has expanded, as has the …
Can features of phosphate toxicity appear in normophosphatemia?
S Osuka, MS Razzaque - Journal of bone and mineral metabolism, 2012 - Springer
Phosphate is an indispensable nutrient for the formation of nucleic acids and the cell
membrane. Adequate phosphate balance is a prerequisite for basic cellular functions …
membrane. Adequate phosphate balance is a prerequisite for basic cellular functions …
An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles
H Ogata, A Takeshima, H Ito - Expert opinion on drug safety, 2022 - Taylor & Francis
Introduction Hyperphosphatemia is an inevitable complication for patients undergoing
dialysis, as is the resulting need for treatment with phosphate binders. Currently, various …
dialysis, as is the resulting need for treatment with phosphate binders. Currently, various …